IDEXX Laboratories (NASDAQ:IDXX) Stock Gets Price Target Reduction from JPMorgan Chase & Co.

IDEXX Laboratories (NASDAQ:IDXX) had its price objective trimmed by JPMorgan Chase & Co. from $775.00 to $750.00 in a research note released on Friday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other research firms also recently issued reports on IDXX. KeyCorp assumed coverage on shares of IDEXX Laboratories in a research report on Monday, October 12th. They issued a “sector weight” rating on the stock. UBS Group boosted their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Finally, The Goldman Sachs Group began coverage on shares of IDEXX Laboratories in a report on Friday. They issued a “buy” rating and a $740.00 target price on the stock. Seven equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $744.09.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $560.36 on Friday. The stock has a market capitalization of $44.15 billion, a PE ratio of 39.41, a price-to-earnings-growth ratio of 2.99 and a beta of 1.55. The business’s fifty day moving average price is $534.22 and its 200 day moving average price is $551.80. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. IDEXX Laboratories has a 12-month low of $500.61 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter in the previous year, the company posted $3.50 earnings per share. The firm’s revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities research analysts forecast that IDEXX Laboratories will post 14.81 EPS for the current year.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the sale, the director directly owned 9,568 shares of the company’s stock, valued at $5,090,941.44. This trade represents a 18.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.79% of the stock is currently owned by insiders.

Hedge Funds Weigh In On IDEXX Laboratories

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp acquired a new stake in IDEXX Laboratories in the 2nd quarter valued at approximately $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in IDEXX Laboratories by 4.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock valued at $479,844,000 after acquiring an additional 39,700 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in IDEXX Laboratories by 52.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock valued at $471,335,000 after acquiring an additional 288,471 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in IDEXX Laboratories by 4.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock worth $322,145,000 after acquiring an additional 23,582 shares during the period. Finally, Alyeska Investment Group L.P. boosted its position in IDEXX Laboratories by 97.3% during the 2nd quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock worth $211,146,000 after acquiring an additional 197,808 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.